总时间（秒）：9.04
问答时间（秒）：8.04

```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "L2020T",
          "alt": "L2020S",
          "position": "858"
        },
        "variant_string_id": "LRRK2 L2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Define Disease Mechanism",
          "extracted_paper_info": "Mutations in LRRK2 are a frequent cause of late-onset autosomal dominant Parkinson’s disease. LRRK2 kinase activity is altered in these mutations, and inhibition of LRRK2 is viewed as a potential therapeutic treatment.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states that mutations in LRRK2 are a frequent cause of late-onset autosomal dominant Parkinson’s disease and that inhibition of LRRK2 is considered a potential therapeutic treatment."
        },
        {
          "step_name": "Evaluate Applicability of General Classes of Assay",
          "extracted_paper_info": "The paper describes binding and enzymatic assays, demonstrating that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP affinity.",
          "judgment": "Yes",
          "reasoning": "The paper details the use of binding and enzymatic assays, highlighting altered kinase activity as a result of mutations in I2020T and G2019S."
        },
        {
          "step_name": "Evaluate Validity of Specific Instances of Assays",
          "extracted_paper_info": "Binding assays, G2019S and I2020T have approximately 2-fold lower and 6-fold higher ATP affinity, respectively, than wild-type LRRK2 . Furthermore, using an in vitro kinase activity assay, we demonstrate that at ATP concentrations close to cellular levels (1 mM) I2020T is approximately 10-fold more resistant to ATP-competitive kinase inhibitors than wild-type whereas G2019S is 1.6-fold more sensitive .6-fold more sensitive.",
          "judgment": "Yes",
          "reasoning": "The paper provides precise values demonstrating the altered ATP affinity of G2019S and I2020T compared to wild-type LRRK2, which is consistent with the hypothesis of altered kinase activity."
        },
        {
          "step_name": "Evaluate Adaptation of the Assay",
          "extracted_paper_info": "The PD-linked mutations I2020T and G2019S, which are located in the activation loop of the kinase domain, have been shown to alter kinase activity.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states that mutations in LRRK2 alter kinase activity, justifying the use of these assays."
        },
        {
          "step_name": "Evaluate Adaptation of the Assay",
          "extracted_paper_info": "Furthermore, using an in vitro kinase activity assay, we demonstrate that at ATP concentrations close to cellular levels (1 mM) I2020T is approximately 10-fold more resistant to ATP-competitive kinase inhibitors than wild-type whereas G2019S is 1.6-fold more sensitive .6-fold more sensitive.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly provides experimental data confirming the increased resistance of I2020T to ATP-competitive kinase inhibitors compared to wild-type LRRK2."
        },
        {
          "step_name": "Determine Impact on Inhibitor Potency",
          "extracted_paper_info": "These results predict that LRRK2 status may impact kinase inhibitor potencies in vivo or in cellular models.",
          "judgment": "Yes",
          "reasoning": "The findings indicate a potential impact of LRRK2 status on kinase inhibitor efficacy, suggesting potential therapeutic implications."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The significantly altered ATP affinity of I2020T and G2019S, as demonstrated through the experimental data, strongly suggests that LRRK2 status significantly impacts kinase inhibitor potency, presenting a promising therapeutic avenue for LRRK2-related Parkinson's disease."
    }
  ]
}
```